
Bridge to Life wins FDA De Novo for transplant liver perfusion system
Bridge to Life has received FDA De Novo clearance for its VitaSmart hypothermic oxygenated perfusion (HOPE) system for liver transplantation.

Bridge to Life has received FDA De Novo clearance for its VitaSmart hypothermic oxygenated perfusion (HOPE) system for liver transplantation.

SonoMotion has received FDA 510(k) clearance for its Break Wave lithotripsy device to treat kidney stones.

Punch-drunk syndrome, boxer’s madness, chronic traumatic encephalopathy (CTE). The name has changed over the years, but the cause is clear: repeated impacts can affect long-term brain health, with symptoms ranging from confusion to memory loss and potentially dementia.

For many women with early breast cancer, surgery is effective but life-altering. New five-year data from the National Institutes for Quantum Science and Technology (QST) suggest that a precisely targeted, high-energy particle therapy may allow some patients to avoid surgery without compromising oncologic outcomes.

An international research team has succeeded in deciphering a key mechanism that controls the growth of pancreatic cancers.

Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells remain largely unknown—yet understanding this is crucial for optimizing patient care.

Researchers from Helmholtz Munich and the Technical University of Munich (TUM) have developed “fast-RSOM,” a new imaging technology that can capture detailed images of the smallest blood vessels directly through the skin—without the need for invasive procedures.

The Xpert GI Panel identifies pathogens directly from stool specimens collected in Cary-Blair transport media.

A new study shows that cancer damages its own DNA by pushing key genes to work too hard. Researchers found that the most powerful genetic “on switches” in cancer cells, called super-enhancers, drive unusually intense gene activity. That high gear creates stress on the DNA and can cause dangerous breaks.

A multidisciplinary team has developed a selective compound that inhibits an enzyme tied to inflammation in people at genetic risk for Alzheimer’s, while preserving normal brain function and crossing the blood-brain barrier.